Cassava Sciences Beheer
Beheer criteriumcontroles 3/4
De CEO Cassava Sciences is Rick Barry, benoemd in Sep2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.98% van de aandelen van het bedrijf, ter waarde $ 1.80M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 6.8 jaar.
Belangrijke informatie
Rick Barry
Algemeen directeur
US$546.2k
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 2yrs |
| Gemiddelde ambtstermijn bestuur | 6.8yrs |
Recente managementupdates
Recent updates
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Nov 07Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02CEO
Rick Barry (65 yo)
less than a year
Tenure
US$546,155
Compensatie
Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$546.16k | 0.98% $ 1.8m | |
| Chief Financial Officer | 6.1yrs | US$2.99m | 0.048% $ 89.5k | |
| Senior VP | 2.1yrs | US$1.27m | 0% $ 0 | |
| Chief Medical Officer | 3.8yrs | US$2.97m | 0.0083% $ 15.4k | |
| Senior Vice President of Technology | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Technical Operations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | 2yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Neuroscience | 4.6yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | no data | geen gegevens | geen gegevens | |
| Chief Clinical Development Officer | no data | geen gegevens | geen gegevens |
2.0yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SAVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 3.4yrs | US$546.16k | 0.98% $ 1.8m | |
| Independent Director | 16.9yrs | US$438.42k | 0.0025% $ 4.6k | |
| Independent Director | 26.4yrs | US$438.42k | 0.017% $ 31.7k | |
| Member of Scientific Advisory Board | 10.1yrs | US$558.31k | geen gegevens | |
| Independent Director | 21.7yrs | US$546.16k | 0.026% $ 48.9k | |
| Independent Chairman | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 |
6.8yrs
Gemiddelde duur
68.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SAVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).